Search hospitals > Oklahoma > Oklahoma City
Oklahoma Medical Research Foundation
Claim this profileOklahoma City, Oklahoma 73104
Global Leader in Systemic Lupus Erythematosus
Global Leader in Lupus
Conducts research for Multiple Sclerosis
Conducts research for Coronary Artery Disease
Conducts research for Arthritis
154 reported clinical trials
6 medical researchers
Summary
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 111 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.Area of expertise
1Systemic Lupus Erythematosus
Global LeaderANA positive
anti-dsDNA positive
anti-Sm positive
2Lupus
Global LeaderANA positive
dsDNA positive
anti-dsDNA positive
Top PIs
Gabriel PardoOklahoma Medical Research Foundation5 years of reported clinical research
Studies Multiple Sclerosis
Studies Syndrome
9 reported clinical trials
17 drugs studied
Cristina Arriens, MD, MSCSOklahoma Medical Research Foundation6 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Lupus
4 reported clinical trials
8 drugs studied
Judith A. James, MD, PhDOklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program6 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Lupus
2 reported clinical trials
5 drugs studied
Christina Arriens, MDOklahoma Medical Research Foundation1 year of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Lupus
2 reported clinical trials
7 drugs studied
Clinical Trials running at Oklahoma Medical Research Foundation
Multiple Sclerosis
Lupus
Systemic Lupus Erythematosus
Shingles
Neuromyelitis Optica (NMO)
Nephritis
Lupus Nephritis
Ocrelizumab
for Multiple Sclerosis
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatment beginning at Month 18: Arm 1: placebo infusions every 6 months; Arm 2: OCR infusions at Months 18 and 24 and then after Month 24 switch to placebo infusions every 6 months; Arm 3: OCR infusions every 6 months. The treatment period will be for a total of 48 months.
Recruiting2 awards Phase 4
Frexalimab
for Multiple Sclerosis
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event-driven study will have variable duration of approximately 40 months for the first participant being randomized and approximately 20 months for the last participant randomized. The study intervention duration will vary ranging from approximately 20 to 40 months. The assessment of scheduled visits will include 1 common end of study [EOS] visit and 3 follow-up visits) with a visit frequency of every 4 weeks for the first 6 months and then every 3 months.
Recruiting1 award Phase 34 criteria
Frexalimab
for Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: This event-driven study will have variable duration ranging from approximately 27 to 51 months. The study intervention duration will vary ranging from approximately 27 to 51 months. The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
Recruiting1 award Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Oklahoma Medical Research Foundation?
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 111 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.